glucosamine has been researched along with Epilepsy Progressive Myoclonic 2 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Allenger, EJ; Armstrong, DD; Brainson, CF; Brewer, MK; Bruntz, RC; Chikwana, VM; Clarke, HA; Conroy, LR; Contreras, CJ; DePaoli-Roach, AA; Drake, RR; Emanuelle, S; Gentry, MS; Hawkinson, TR; Hurley, TD; Johnson, LA; Macedo, JKA; Mahalingan, KK; Markussen, KH; Mestas, A; Roach, PJ; Rondon, AL; Sanders, WC; Segvich, DM; Shaffer, R; Stanback, AE; Sun, RC; Tang, B; Taylor, RE; Vander Kooi, CW; Waechter, CJ; Young, LEA; Zhou, Z | 1 |
1 other study(ies) available for glucosamine and Epilepsy Progressive Myoclonic 2
Article | Year |
---|---|
Brain glycogen serves as a critical glucosamine cache required for protein glycosylation.
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Female; Glucosamine; Glycogen; Glycogen Synthase; Glycogenolysis; Glycosylation; Lafora Disease; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Processing, Post-Translational | 2021 |